Eleonora Foglio

Eleonora Foglio

Auto-generated profile, based on publicly available information

Eleonora Foglio

Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
LPLaura Pellegrini
Laura Pellegrini
EFEleonora Foglio
Eleonora Foglio
EPElena Pontemezzo
Elena Pontemezzo
AGAntonia Germani
Antonia Germani
MRMatteo Antonio Russo
Matteo Antonio Russo
FLFederica Limana
Federica Limana

1 October 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
EFEleonora Foglio
Eleonora Foglio
GPGiovanni Puddighinu
Giovanni Puddighinu
PFPasquale Fasanaro
Pasquale Fasanaro
DDDaniela D’Arcangelo
Daniela D’Arcangelo
GPGiulietta A. Perrone
Giulietta A. Perrone
FLFederica Limana
Federica Limana

8 October 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Marco PrestaMarco Presta
Marco Presta
EFEleonora Foglio
Eleonora Foglio
ASAnder Churruca Schuind
Ander Churruca Schuind
RRRoberto Ronca
Roberto Ronca
Angiogenesis, the process of new blood vessel formation from pre-existing ones, plays a key role in various physiological and pathological conditions. Alteration of the angiogenic balance, consequent to the deranged production of angiogenic growth factors and/or natural angiogenic inhibitors, is responsible for angiogenesis-dependent diseases, including cancer. Fibroblast growth factor-2 (FGF2) represents the prototypic member of the FGF family, able to induce a complex “angiogenic phenotype” in endothelial cells in vitro and a potent neovascular response in vivo as the consequence of a tight cross talk between pro-inflammatory and angiogenic signals. The soluble pattern recognition receptor long pentraxin-3 (PTX3) is a member of the pentraxin family produced locally in response to inflammatory stimuli. Besides binding features related to its role in innate immunity, PTX3 interacts with FGF2 and other members of the FGF family via its N-terminal extension, thus inhibiting FGF-mediated angiogenic responses in vitro and in vivo. Accordingly, PTX3 inhibits the growth and vascularization of FGF-dependent tumors and FGF2-mediated smooth muscle cell proliferation and artery restenosis. Recently, the characterization of the molecular bases of FGF2/PTX3 interaction has allowed the identification of NSC12, the first low molecular weight pan-FGF trap able to inhibit FGF-dependent tumor growth and neovascularization. The aim of this review is to provide an overview of the impact of PTX3 and PTX3-derived molecules on the angiogenic, inflammatory, and tumorigenic activity of FGF2 and their potential implications for the development of more efficacious anti-FGF therapeutic agents to be used in those clinical settings in which FGFs play a pathogenic role.

23 November 2011 in AGE
Verified
Journal Article
Closed access
PDF file
Luigi Fabrizio RodellaLuigi Fabrizio Rodella
Luigi Fabrizio Rodella
Gaia FaveroGaia Favero
Gaia Favero
CRClaudia Rossini
Claudia Rossini
EFEleonora Foglio
Eleonora Foglio
FBFrancesca Bonomini
Francesca Bonomini
Rita RezzaniRita Rezzani
Rita Rezzani

10 January 2012 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
NPNitin Puri
Nitin Puri
KSKomal Sodhi
Komal Sodhi
MHMichael Haarstad
Michael Haarstad
DKDong Hyun Kim
Dong Hyun Kim
SBSteven Bohinc
Steven Bohinc
NANader G. Abraham
Nader G. Abraham

21 September 2016 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
EFEleonora Foglio
Eleonora Foglio
GPGiovanni Puddighinu
Giovanni Puddighinu
AGAntonia Germani
Antonia Germani
MRMatteo A. Russo
Matteo A. Russo
FLFederica Limana
Federica Limana